Whitepaper

Article | In Vitro Bioequivalence for Pulmonary and Nasal Delivery

Download

PDF 244 kB

Article | In Vitro Bioequivalence for Pulmonary and Nasal Delivery

With a focus on bioequivalence testing in the development of generic inhalables, Mark Parry, Technical Director, Intertek Melbourn, highlights some of the shortcomings of aerodynamic particle size distribution and delivered dose testing, and introduces newer testing techniques that Intertek offers to allow its clients to de-risk clinical studies or even to support robustly in vitro data submissions as to avoid clinical work.

Other Content from Intertek Analytical Services